Crossmark

Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial

Crossref DOI link: https://doi.org/10.1136/bmjpo-2023-001913

Published Online: 2023-05-08

Published Print: 2023-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Fayoux, Pierre https://orcid.org/0000-0002-0740-4580
Dinomais, Mickael https://orcid.org/0000-0002-6980-1178
Shaw, Helen https://orcid.org/0000-0001-7660-3930
Probert, Nick

Villain, Frédéric https://orcid.org/0000-0002-6492-8153
Pouchain, Denis https://orcid.org/0000-0001-6882-3474
Texier, Nathalie https://orcid.org/0000-0003-3749-254X
Auvin, Stéphane https://orcid.org/0000-0003-3874-9749
Funding

Funding for this research was provided by:

Proveca Ltd (No award/grant number)
License Information

License valid from 2023-05-08